Chemotherapy for esophageal cancer with mitoguazone, methotrexate, bleomycin, and cisplatin

S. E. Vogl, F. Camacho, M. Berenzweig, J. Ruckdeschel

Research output: Contribution to journalArticle

7 Scopus citations

Abstract

Eighteen patients with measurable or evaluable lesions from squamous cancer of the esophagus received a regimen combining four active agents on an outpatient basis. Nine of 14 evaluable patients (64%, or 50% of 18 patients entered) responded: four of five with previously untreated regional disease and five of nine with recurrent or metastatic disease. Median duration of response in the latter group was 5 months (longest response, 13). Treatment was well-tolerated in all patients but one, who developed signs of severe methotrexate toxicity and died of sepsis.

Original languageEnglish (US)
Pages (from-to)21-23
Number of pages3
JournalCancer Treatment Reports
Volume69
Issue number1
StatePublished - Jan 1 1985

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Chemotherapy for esophageal cancer with mitoguazone, methotrexate, bleomycin, and cisplatin'. Together they form a unique fingerprint.

  • Cite this